News

Rotarix is an oral, two-dose, live attenuated vaccine against rotavirus disease in infants that was licensed in 1997 by Avant Immunotherapeutics to GSK for worldwide commercialization. Rotavirus infection

Detailed financial terms were not disclosed, but include upfront, annual and milestone payments, all in cash, and royalties on sales of any products that result from the licensing

GX15-070 is a novel, targeted cancer treatment designed to induce apoptosis (natural cell death) by inhibiting the Bcl-2 family of proteins, one of the most validated and well-studied

The open-label, dose-escalation study conducted at two major cancer treatment centers is designed to evaluate the safety and tolerability of the small molecule Aurora kinases inhibitor VX-680 when

Echelon’s product pipeline is focused on the rapidly emerging field of transduction signalling technology. It has early therapeutic leads (mostly direct PI3K inhibitors) against some forms of cancer

Tamoxifen is a cytostatic oestrogen receptor antagonist used extensively for the treatment of hormonally sensitive breast cancer. Soltamox is the only oral liquid presentation of tamoxifen licensed in

The drug candidate, PA-457, is the first in a new class of HIV drugs called maturation inhibitors. In granting fast track status for the form of PA-457 that

Under the agreement, Novartis has made a significant equity investment in Infinity and will pay additional fees expected to exceed $10 million over the course of the two

PolyMedix plans to file an investigational new drug (IND) application and to initiate human clinical trials of the compound later this year. In addition, the company plans to